A phosphonate pendant-armed cross-bridged cyclam chelator has been synthesized, complexed to Cu(II), radiolabeled with 64 Cu under mild conditions, and its biodistribution studied.
The family of ethylene cross-bridged cyclam macrobicycles has received increasing attention as chelators in radiopharmaceutical research. 1,2 An especially promising ligand for radio-copper binding is the dicarboxymethyl pendant-armed ligand 1 (CB-TE2A, Fig. 1 ) which imparts remarkable kinetic inertness to its Cu(II) complex resulting in superior in vivo behavior of its 64 Cu-labeled bioconjugates. 3,4 However, its sluggish radiolabeling kinetics has necessitated the use of relatively harsh protocols (e.g. 85 • C, pH 8, 1 h). While still practicable for bioconjugates of some biological targeting vectors, 5 these severe labeling conditions have precluded the use of more sensitive peptides or biomolecules. Phosphonate pendant-armed cyclen and cyclam derivatives have been reported to have accelerated metal-binding kinetics relative to their carboxylate-armed analogues while retaining high thermodynamic stabilities of their complexes. 6- 10 We report here the synthesis and characterization of a di-methanephosphonate pendant-armed cross-bridged cyclam 2 (CB-TE2P), its Cu(II) complex as well as its 64 Cu radiolabeling and in vivo biodistribution studies. Diffusion of acetone into an aqueous solution gave crystals of H 2 2·HCl·4H 2 O suitable for X-ray crystallography. The structure (Fig. 2) shows the ligand to be di-inside-protonated and the two phosphonate arms to be intramolecularly O-H ◊ ◊ ◊ O hydrogen bonded. The ligand adopts a [2233]/[2233] conformation rather than the [2323]/[2323] conformation, 13,14 perhaps in order to facilitate the appropriate arm-arm distance for the intramolecular H-bond.
The Cu(II) complex of 2 was first prepared from CuCl 2 and the ligand in refluxing methanol with the pH adjusted to 8 using aqueous NaOH. Subsequently, it was found that complexation in methanol was actually complete in less than 5 min at ambient temperature. The blue complex (l max (MeOH)/nm 639 (e/dm 3 mol -1 cm -1 35)) was studied by cyclic voltammetry in 0.1 M aq. NaOAc. It exhibited a quasi-reversible reduction at -0.96 V (Ag/AgCl), typical of Cu(II) cross-bridged cyclam complexes. 15 Its acid inertness was assayed under pseudo first-order conditions in 5 M HCl at 90 • C and found to have a half life of 3.8(1) h. While this is considerably shorter than the 154 h previously reported for Cu-1, it is significantly more inert than Cu-DOTA and Cu-TETA, both of which were completely decomplexed within minutes. 15 The X-ray crystal structure of Cu-2 ‡ is shown in Fig. 3 . Even though 2 showed rapid Cu 2+ complexation in methanol and ethanol, the radiolabeling experiments with 64 Cu were performed in water or aqueous buffers since organic solvents are not well tolerated by animals and therefore less convenient for in vivo experiments. No-carrier-added 64 Cu-2 was prepared in water by addition of a solution of 64 CuCl 2 in 0.1 M HCl to a 2-5 mM solution of the ligand in water. We found that radio-TLC was not adequate for determining labeling purity as it only differentiated between free and chelated 64 Cu. By contrast, radio-HPLC was able to resolve whether more than one product formed. Thus at room temperature, "exo-complexes" (vide infra) were observed, while 100% formation of the fully-engulfed complex was obtained at higher temperatures (>90 • C) as confirmed by LC-MS and radio-LC-MS compared to an authentic sample. Under carrier-added conditions (molar ratio of ligand/Cu 2+ = 100 : 35) 64 Cu-2 formed in a 100% yield even at room temperature.
Under no-carrier-added conditions (molar ratio of ligand/ Cu 2+ > 10 5 :1) radioactive peaks were observed by LC-MS at lower retention times than that of 64 Cu-2. This is attributed to the slower kinetics of complex formation with extremely low concentrations of Cu 2+ (nM to pM). One hypothesis is that the formation of "exo" or "out of cleft" complexes occurs initially, rather than the fully encapsulated form that is shown in the crystal structure. At this stage the Cu 2+ is only bound to one or more of the pendant arms, and its coordination sphere is likely to contain water molecules, while some of the nitrogen atoms in the macrocycle remain protonated. The conversion to the thermodynamically stable final complex is a slower process that can be accelerated either by increasing copper concentration (carrier-added conditions) or by heating.
Another possibility is the presence of trace level impurities (< 1%) that bind 64 Cu 2+ more rapidly than 2. Adding cold copper saturates the impurities and the thermodynamically favored 64 Cu-2 preferentially forms. Increasing the temperature also favors the formation of the desired complex due to its superior thermodynamic stability. A similar hypothesis was formulated in 2005 by Boswell et al. 17 for the labeling of compound 1.
In order to gain an insight into the pharmacokinetics of 64 Cu-2, a biodistribution study was performed on 26-day-old Lewis male rats. 64 Cu-2 (50 mCi (~1 mCi/mg) in 150 mL of saline) was injected through the tail vein, and the animals were sacrificed at 1, 2, 4 and 24 h after injection. The organs were harvested and their activity measured with a g counter.
As shown in Fig. 4 , the radiolabeled compound clears rapidly from the blood (from 0.15% ID/g at 1 h to 0.002 ID/g at 24 h) and has only minor residual uptake in organs such as liver, spleen, lung, heart and marrow (not higher than 0.03% ID/g at 24 h). Rapid clearance of 64 Cu-2 from the liver is indicative of its high in vivo stability, as it is known that dissociated 64 Cu is rapidly coordinated by liver proteins such as SOD, ceruloplasmin and metallothionein. 18 The biodistribution data demonstrate that 64 Cu-2 is rapidly excreted through the kidney, where there is 0.36% ID/g after 24 h. Not surprisingly, at earlier time points a significant percentage of radioactivity was observed in the bone, most likely due to the affinity of the methanephosphonic pendant arms for the hydroxyapatite in the bone; however, this activity is cleared severalfold by 24 h post-injection. Similar results were obtained for methanephosphonic derivatives of cyclen. 9 Unlike the recently-reported 4,11-dimethyl-cyclam-1,8bis(methylphosphonic acid), 10 chelator 2 forms a sufficiently inert Cu(II) complex for radiopharmaceutical applications. Syntheses and bioconjugation of unsymmetrically functionalized monophosphonate cross-bridged cyclam are under active investigation in our laboratories and will be reported in due course.
